Search Result

Results for "

p97 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	p97 (16) Apoptosis (2) ATP Synthase (2) Autophagy (1) JAK (1)
By Research Areas:	Cancer (17) Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Targets Recommended: p97

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19797A

ML241 hydrochloride	p97	Cancer
ML241 hydrochloride is a potent *p97* inhibitor, inhibiting p97 ATPase with IC₅₀ value of 100 nM.

HY-19795

ML240 3 Publications Verification	p97	Cancer
ML240 is a potent *p97* inhibitor, inhibiting p97 ATPase with IC₅₀ value of 100 nM.

HY-15945

DBeQ 3 Publications Verification JRF 12	p97 Autophagy Apoptosis	Cancer
DBeQ is a selective, potent, reversible, and ATP-competitive *p97* inhibitor, with an IC₅₀ value of 1.5 μM and 1.6 μM for p97(wt) and p97(C522A), respectively; DBeQ also inhibits Vps4 with an IC₅₀ of 11.5 μM.

HY-11067

WHI-P97 2 Publications Verification	JAK	Inflammation/Immunology
WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .

HY-128724

CB-5339	p97	Cancer
CB-5339 is an oral activity potent *p97* inhibitor with an IC₅₀ <30 nM. CB-5339 can be used for leukemia research . CB-5339 extracted from WO2015109285A1 compound FF07.

HY-123636

UPCDC-30245	p97	Cancer
UPCDC-30245 is an allosteric p97 inhibitor with an IC₅₀ of approximately 27 nM . UPCDC-30245 inhibits the p97 mutant N660K similar to wild type (WT; IC₅₀=300 nM) and shows 3-fold resistance for p97 mutant T688A . UPCDC-30245 can be used in the research of cancer .

HY-139606

*VCP/p97* inhibitor-1**	p97	Cancer
VCP/p97 inhibitor-1 is a potent inhibitor of *VCP/p97* (also called Cdc48, CDC-. 48, or Ter94) with an IC₅₀ of 54.7 nM. VCP/p97 inhibitor-1 causes the dysregulation of protein homeostasis and disturbs the degradation of misfolded polypeptides by the ubiquitin-proteasome system (UPS) .

HY-168005

NSC799462	p97 ATP Synthase	Cancer
NSC799462 is a triazole inhibitor of p97 ATPase. NSC799462 inhibits p97 ATPase activity (IC₅₀ = 15 nM) by binding to a specific site on *p97* and causing local changes in the *p97* structure .

HY-168006

NSC819701	p97 ATP Synthase	Cancer
NSC819701 is a triazole inhibitor of the p97 ATPase. NSC819701 inhibits the activity of p97 ATPase by binding to a specific site of *p97* .

HY-148122

NW 1028	p97	Cancer
NW 1028 is a potent *VCP/p97* inhibitor. NW 1028 targets the ND1L domain of p97 and inhibits the degradation of a p97-dependent reporter. NW 1028 has good binding affinity with K_d values of 100 and 285 nM for ND1L and full length p97, respectively. NW 1028 has the function of regulating the mitotic spindle of cells .

HY-12861

CB-5083 Maximum Cited Publications 22 Publications Verification	p97	Cancer
CB-5083 is a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase/VCP. CB-5083 selectively inhibits p97 through its D2 site with the IC₅₀ of 11 nM .

HY-123872

MSC1094308	p97	Cancer
MSC1094308 is a non-competitive and reversible *VPS4B/p97* (VCP)** (I/II type AAA ATPase) allosteric inhibitor, with IC₅₀ values of 0.71 μM and 7.2 μM for VPS4B and *p97, respectively . MSC1094308 inhibits* the D2 ATPase activity by binding to a agentable hotspot of *p97*. MSC1094308 can be used in study of cancer .

HY-15713

NMS-873 5+ Cited Publications	p97	Cancer
NMS-873 is a potent, selective allosteric *VCP/p97* inhibitor with an IC₅₀ value of 30 nM.

HY-19797

ML241	p97	Cancer
ML241 is a potent, selective and competitive p97 ATPase inhibitor with an IC₅₀ of 0.11 μM. ML241 can be used for the research of cancer .

HY-15714

NMS-859	p97	Cancer
NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC₅₀s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.

HY-124776

NPD8733	Others	Cancer
NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration. NPD8733 specifically binds to valosin-containing protein (VCP)/p97, a member of the ATPase-associated with diverse cellular activities (AAA+) protein family. NPD8733 has the potential for the research of cancer diseases .

HY-155026

UPCDC30766	p97	Cancer
UPCDC30766 is a potent allosteric inhibitor of *p97, with an IC₅₀* of 12 nM. UPCDC30766 can be used for the research of colon cancer . UPCDC30766 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-110078

Eeyarestatin I 3 Publications Verification	p97 Apoptosis	Cancer
Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I inhibits Sec61 translocon. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I interferes at a step prior to proteasomal degradation. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects .

Cat. No.	Product Name

HY-L050

Ubiquitination Compound Library	258 compounds
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc. MCE offers a unique collection of 258 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Ubiquitination Compound Library

258 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 258 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.